41 results about "Hidradenitis" patented technology

The invention relates to a traditional Chinese medicine for treating hidradenitis suppurativa. The traditional Chinese medicine is prepared from the following medicinal materials in parts by weight: 15 parts of mucuna paohwashanica, 14 parts of ficus hispida L. f., 14 parts of colocasia antiquorum schott, 10 parts of begonia palmata, 12 parts of celastrus angulata maxim, 12 parts of crotalaria albida heyne, 12 parts of rabdosia, 12 parts of white gentian, 14 parts of anemone rivularis buch, 15 parts of oxalis rubra, 8 parts of piper wallichii, 15 parts of hypericum uralum, 12 parts of claoxylon polot merr, 10 parts of anemome tomentosa, 10 parts of Ixeris polycephala, 5 parts of peltate yam rhizome, 8 parts of stichopus japonicus, 10 parts of excoecaria venenata and 10 parts of rubus irenaeus focke. The clinical trial proves that the traditional Chinese medicine can safely and effectively treat hidradenitis suppurativa.

This invention relates to Ligulatrovine A separated from Ligularia actroviolacea that can prevent and treat diseases related to Staphylococcus aureus and beta hemolytic streptococcus, its pharmaceutical salts and drug composition. Ligulatrovine A has significant inhibitive effect on Gram-positive bacteria, and can prevent and treat diseases such as boil, pustule, pneumonia, osteomyelitis, acute myocarditis, endocarditis, meningitis, mastitis, cystitis, pelvic inflammation, urinary inflammation, prostatitis, bacteremia, or abscess in muscle, skin, urogential region or central nervous system caused by Gram-positive bacteria infection.

The invention discloses an externally applied traditional Chinese medicine powder for diminishing inflammation and swelling, which is prepared from the following raw material medicines by weight percentage: 20-30% of realgar, 25-35% of rhubarb, 10-20% of turmeric, 10-20% of cortex phellodendri, and 10-20% of bulbus fritillariae thunbergii. The externally applied powder for diminishing swelling isprepared by the compatibility of only five raw material medicines, has the efficacies of promoting blood circulation and removing blood stasis, diminishing swelling and relieving pain, expelling stasis and stagnation, and promoting pus discharge and tissue regeneration. The externally applied traditional Chinese medicine powder is simple in compatibility, distinct in treatment effect, and short in course of treatment, and does not have toxic or side effect. The externally applied powder for diminishing swelling can treat acute and chronic lobular hyperplasia of mammary glands, lymphnoditis, mumps, traumatic injuries, lipoma, furuncle, pustule of finger tip, paronychia, tinea unguium, external piles, anus abscess and hemangioma, with wide treatment range and low cost, and also can be used for treating mammary gland disease and foot-and-mouth disease of cows, with very good treatment effect.

This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

The present invention discloses one kind of Chinese herbal medicine digestant for treating lymphoid tuberculosis and lymphadenitis, and the Chinese herbal medicine digestant is prepared with asparagus 6-10 weight portions, burrerfly bush flower 9-12 weight portions, Chinese sumac 10-15 weight portions, dandelion 2-4 weight portions, mullein nightbrier leaf 1-2 weight portions, and Chinese honeylocust spine 1-3 weight portions. It is used in treating lymphoid tuberculosis and lymphadenitis, and has high curative effect and no toxic side effect.

A novel polypeptide, and an antibacterial agent, antifungal agent and / or antiseptic containing as an effective ingredient the polypeptide are disclosed. The polypeptide of this invention has an amino acid sequence shown in SEQ ID NOs:1 to 12 and 13 to 31. This antibacterial agent, antifungal agent and / or antiseptic is useful for the prevention, amelioration or treatment of diseases such as burn, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliterans, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, skin abscess, necrotizing subcutaneous infection, staphylococcal scalded skin syndrome (SSSS), folliculitis, facial furuncle, suppurative hidradenitis, carbuncle, infectious paronychia, erythrasma and severe infection (sepsis).

The invention provides a pharmaceutical compound. The pharmaceutical compound is a compound shown in the following structural formula or a stereoisomer, a geometrical isomer, a tautomer, a racemate, ahydrate, a solvate, a metabolite and a pharmaceutically acceptable salt or prodrug thereof shown in the specification, wherein R represents 1 to 3 substituents on a benzene ring, and each of the 1 to3 substituents is independently selected from halogen or cyano. The pharmaceutical compound provided by the invention can inhibit JAK kinase, and more particularly can be used as a JAK1 / Tyk2 dual inhibitor and a Tyk2 specific inhibitor. More specifically, the pharmaceutical compound provided by the invention can be used for preventing or treating autoimmune diseases such as rheumatoid arthritis,ankylosing spondylitis, ulcerative colitis, systemic lupus erythematosus, type I diabetes, sicca syndrome, vasculitis, alopecia areata, psoriasis, leucoderma and the like, or other inflammatory skin diseases such as atopic dermatitis, eczema, acne and hidradenitis suppurativa.

Compositions and methods for treating skin conditions, ailments or diseases, such as autoinflammatory skin diseases such as psoriasis, dermatitis, pyoderma gangrenosum, palmoplantar pustulosis, prurigo nodularis and / or hidradenitis suppurativa, are described. The compositions comprise an agent that modulates the aryl hydrocarbon receptor, in particular an agent that agonizes the receptor. In one embodiment, the agent is indigo or a derivative of indigo, such as indirubin.

Compositions and related methods of treating diseases of the pilosebaceous unit including acne, rosacea and hidradenitis. Through the introduction of active ingredients including xylitol and farnesol at a treatment location, biofilms associated with acne, roasacea and hidradenitis are disrupted and / or inhibited. The composition can be in the form of a topical medication or cream including a pharmaceutically acceptable carrier and the active ingredients. The composition can further comprise beneficial skin supplements to further enhance the treatment effects. The composition can be utilized in conjunction with additional biofilm disruption treatments.

The invention discloses powder for drawing out toxin. The powder for drawing out toxin is prepared from the following traditional Chinese medicines by weight: 10 parts of cortex phellodendri, 10 parts of radix angelicae, 10 parts ofalum, 20 parts of mirabilite, 20 parts of rheum officinale and 10 parts of gypsum rubrum. The powder for drawing out the toxin is prepared by rinsing the above traditional Chinese medicines, drying, smashing into 200 meshes, adding a proper amount of sesame oil; mixing uniformly and blending into a paste. In the powder for drawing out the toxin, unique effects and synergistic effects of the traditional Chinese medicines are played, and the functions of clearing heat and removing toxicity, activating blood and resolving stasis, and dispersing swelling and softening hardness can be achieved. The powder for drawing out the toxin has a rapid curative effect, and is mainly used for symptoms such as abscess, acute cellulitis, acute / chronic parotitis, mammitis, hyperplasia of mammary glands, lymphnoditis, lumbar muscle degeneration, scapulohumeral periarthritis, soft tissue contusion, gout, etc.

The invention discloses a traditional Chinese medicine for treating yin deficiency type hidradenitis suppurativa. The traditional Chinese medicine is characterized by being prepared from the following medicinal materials in parts by weight: 20 parts of thick yellow grass, 15 parts of balanophora polyandra griff, 15 parts of sword-leaved cymbidium leaves, 15 parts of white rheum forrestii, 22 parts of wall spider egg-case, 18 parts of sedum sarmentosum, 12 parts of adina rubella hce, 20 parts of nakedflower beautyberry branchlet and leaf, 18 parts of caulopterum yamazaki, 10 parts of berberis amurensis, 10 parts of stem of Chinese viburnum, 20 parts of abelmoschus sagittifolius leaves, 15 parts of orchis, 15 parts of small caulis dendrobii, 15 parts of viola mandshurica, 15 parts of euonymus oxyphyllus, 15 parts of longipetiolata, 12 parts of decumbent bugle herb, 15 parts of cottonrose hibiscus leaves, 8 parts of carex cruciate, 15 parts of salvia roborowskii maxim, 15 parts of carpinus cordata blume, 18 parts of astragalus, 15 parts of fructus oryzae germinates and 6 parts of liquorice. The traditional Chinese medicine for treating the yin deficiency type hidradenitis suppurativa, disclosed by the invention, has a good treatment effect and causes no relapse after the yin deficiency type hidradenitis suppurativa is cured.

A dripping pill of senecio for treating acute conjunctitis, acute pharyngolaryngitis, acute tonsillitis, acute enteritis, acute bacterial dycentery, upper respiratory tract inflammation, etc is prepared from senecio. Its preparing process is also disclosed.

The present invention, in some embodiments thereof, relates to treatment of hidradenitis suppurativa by topical or intralesional administration of a composition comprising tapinarof and optionally at least one additional active agent. The composition of the present invention is useful for the treatment, prevention or amelioration of hidradenitis suppurativa.

The invention relates to the technical field of medical treatment, in particular to an in-vitro skin model for studying hidradenitis suppurativa and a preparation method thereof. The in-vitro skin model comprises a base, a simulated fat layer is installed on the upper surface of the base, a simulated corium layer is installed on the upper surface of the simulated fat layer, and the simulated corium layer and the simulated fat layer are bonded together through a pressure-sensitive adhesive; the simulated dermis layer is internally provided with simulated subcutaneous blood vessels, the upper surface of the simulated dermis layer is provided with a simulated epidermal layer, the simulated epidermal layer and the simulated dermis layer are bonded together through a pressure-sensitive adhesive, the simulated dermis layer is internally provided with simulated erector hair muscles, the end parts of the simulated erector hair muscles are connected with the middle parts of the simulated hair follicles, the simulated corium layer and the simulated fat layer can be directly separated, after research is finished, the simulated corium layer is placed on the simulated fat layer again, pressure is applied to enable the simulated corium layer and the simulated fat layer to be bonded together again, and the simulated corium layer and the simulated fat layer are very convenient to observe and research.

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds (collectively referred to herein as CHMSA compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, hidradenitis suppurativa, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

The invention discloses a tradtional Chinese medicament for treating heart-spleen deficiency type hidradenitis suppurative. The tradtional Chinese medicament is characterized by being prepared from the following medicinal materials in parts by weight: 15 parts of phtheirospermum tenuisectum, 20 parts of celastrus flagellaris fruit, 15 parts of acanthopanax obovatus hoo, 20 parts of king pedicularis root, 18 parts of polygala fallax hemsl, 15 parts of wall spider's egg-case, 10 parts of white-haired paederia, 10 parts of root of spiny raspberry, 15 parts of cayratia trifolia, 15 parts of beautyberry leaf, 12 parts of berberis amurensis, 15 parts of breynia retusa dennst alston, 8 parts of sanguinolenta, 15 parts of Wuzhishan ginseng leaf, 12 parts of lespedeza tomentosa, 15 parts of ficus formosana root, 18 parts of crepis crocea, 12 parts of viola mandshurica, 12 parts of longan seeds, 12 parts of root of false indigo herb, 10 parts of didymocarpus hedyotideus chun, 10 parts of quisqualis leaf, 10 parts of glossogyne tenuifolia, 15 parts of radix cynanchi bungei, 15 parts of ivy glorybind herb root and 5 parts of licorice. The tradtional Chinese medicament for treating heart-spleen deficiency type hidradenitis suppurative has a good treatment effect and avoids relapse after healing.

Methods and compositions for alleviating treating bromhidrosis, hyperhidrosis, hidradenitis supportiva, and related conditions of the hair follicle are contemplated via the administration of at least one pharmacologically active bile acid to the area of skin containing the apocrine or eccrine glands causing such conditions. The detergent effect of the bile acid is operative to destabilize and permanently render these glands biologically inactive, substantially disrupting sweat production in the treated area, thus alleviating the treated condition. Topical and injectable formulations and methods of administrations are contemplated, along with various therapeutic regiments.

The invention relates to a traditional Chinese medicine composition for treating necrotizing lymphadenitis and application thereof. A traditional Chinese medicine composition for treating initial necrotizing lymphadenitis is prepared from 50-70 parts of lonicera japonica, 20-40 parts of bombyx batryticatus, 50-70 parts of radix astragali, 20-40 parts of rhizoma phragmitis, 20-40 parts of fructus forsythiae and 15-25 parts of mint. A traditional Chinese medicine composition for treating mid-term necrotizing lymphadenitis is prepared from 50-70 parts of lonicera japonica, 20-40 parts of bombyx batryticatus, 50-70 parts of radix astragali and 20-40 parts of rhizoma phragmitis. A traditional Chinese medicine composition for treating later necrotizing lymphadenitis is prepared from 50-70 parts of lonicera japonica, 20-40 parts of bombyx batryticatus, 50-70 parts of radix astragali, 20-40 parts of rhizoma phragmitis, 50-70 parts of prunella vulgaris, 20-40 parts of rhizoma sparganii and 20-40 parts of rhizoma curcumae. According to the traditional Chinese medicine composition, pathogenesis is hit, the curative effect is obvious, the medicinal odor component is small, preparing is convenient, the cost is low, and therefore the traditional Chinese medicine composition is suitable for application and popularization in clinic.

This invention relates to Ligulatrovine A separated from Ligularia actroviolacea that can prevent and treat diseases related to Staphylococcus aureus and beta hemolytic streptococcus, its pharmaceutical salts and drug composition. Ligulatrovine A has significant inhibitive effect on Gram-positive bacteria, and can prevent and treat diseases such as boil, pustule, pneumonia, osteomyelitis, acute myocarditis, endocarditis, meningitis, mastitis, cystitis, pelvic inflammation, urinary inflammation, prostatitis, bacteremia, or abscess in muscle, skin, urogential region or central nervous system caused by Gram-positive bacteria infection.

Compositions and methods for treating skin conditions, ailments or diseases, such as autoinflammatory skin diseases such as psoriasis, dermatitis, pyoderma gangrenosum, palmoplantar pustulosis, prurigo nodularis and / or hidradenitis suppurativa, are described. The compositions comprise an agent that modulates the aryl hydrocarbon receptor, in particular an agent that agonizes the receptor. In one embodiment, the agent is indigo or a derivative of indigo, such as indirubin.

The invention relates to the technical field of traditional Chinese medicine and particularly discloses a traditional Chinese medicine for treating neck chronic lymphadenitis of children. The traditional Chinese medicine comprises the following components in parts by weight: 10-15 parts of rheum officinale, 4-6 parts of burdocks, 2-3 parts of pangolin, 1 part of borneol, 1 part of scorpio, 1 part of radix angelicae and 0.5 part of indigo naturalis. In the formula, rheum officinale and burdocks which are monarch drugs are mainly used for promoting blood circulation to remove blood stasis, eliminating carbuncle and removing stasis; pangolin and scorpio which are ministerial drugs are added for mainly enhancing the function of dredging collaterals and removing stasis; indigo naturalis is an assistant drug which has the function of dredging collaterals; radix angelicae which is a supplementary inhibitory drug has the function of warming and removing stasis and can alleviate the cold and cool effect of the whole formula; borneol which is a guide drug is fragrant and disperse and easy to permeate. The medicines are used together for promoting blood circulation to eliminate carbuncle, dredging collaterals and removing stasis, is spicy and migratory and has the function of eliminating swelling and removing stasis. The traditional Chinese medicine disclosed by the invention is simple to prepare, good in absorption effect, remarkable in curative effect, free of side effects and high in safety and can be easily accepted by parents, thereby facilitating quick alleviation of symptoms of the patient.

The invention relates to wikstroemia indica tincture. The tincture is formed by brewing wikstroemia indica in alcohol. The wikstroemia indica tincture disclosed by the invention has the effects of detoxification, inflammation diminishing and insect killing. A preparation method of the wikstroemia indica tincture is simple; the raw material is single and readily available. The wikstroemia indica tincture is mainly used for treating sore carbuncle, skin itching, insect biting, bee sting, various inflammations on the body surface, lymphnoditis and parotitis.

The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating hidradenitis suppurativa, by employing CD40 antagonists, such as anti-CD40 antibodies.

The present disclosure relates to methods for treating Hidradenitis Suppurativa using a LTA4H inhibitor. Also disclosed herein are LTA4H inhibitors, for treating Hidradenitis Suppurativa patients, as well as medicaments, dosing regimens, pharmaceutical formulations, combinations, dosage forms, and kits for use in the disclosed uses and methods.

The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and / or solvate thereof, for use in the prevention and / or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and / or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.

The present invention relates to flavonoid glycosides isolated from dandelion and capable of preventing and treating Staphylococcus aureus and beta-hemolytic streptococcus infection diseases and their pharmaceutically acceptable salts, their anti-infective medicinal uses, and pharmaceutical compositions containing these compounds. The two novel flavonoid glycoside compounds of the present invention have obvious effects of inhibiting the growth of Staphylococcus aureus and beta-hemolytic streptococcus, and can be expected to be used for the prevention and treatment of boils, pustules and toxic epidermal decomposition caused by the infection of these two. , pneumonia, osteomyelitis, acute myocarditis, endocarditis, meningitis, mastitis, cystitis, pelvic inflammatory disease, urinary tract inflammation, prostatitis, bacteremia, toxic shock syndrome, lymphadenitis, arthritis, pharyngitis , cervicitis, and muscle, skin, urogenital tract, central nervous system abscesses.

Methods of treating hidradenitis suppurativa using compounds and analogs that inhibit certain kinases, including Janus kinase (JAK).

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-acyl-{4-[(4-aryl- phenyl)sulfonylmethyl]piperidine} compounds of the following formula (collectively referred to herein as NASMP compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), Hidradenitis suppurativa, autoimmune hepatitis, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

The present disclosure relates to a method for reducing circulating neutrophils in a subject without causing sustained grade 3 or grade 4 neutropenia. The present disclosure also relates to methods for treating neutrophilic conditions with an antibody that inhibit G-CSF signalling. In particular, the present disclosure relates to methods of 5 treating neutrophilic dermatoses, such as hidradenitis suppurativa (HS) and palmoplantar pustulosis (PPP).